Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine in Treatment-Naïve Higher-Risk MDS
NCT02942290Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in myelodysplastic syndrome (MDS), sponsored by AbbVie Inc. Primary endpoints: Area Under the Curve from Time Zero to the Last Measurable Concentration up to 32 days, Maximum Observed Plasma Concentration up to 32 days and 7 more. Started Jan 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02942290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942290.